Dr. Bruce W. Bode, M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Medical school
- Emory University School of Medicine (1981)
- Years since graduation
- 45
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 850
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1981Medical school: Emory University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
GA license 023909
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Piedmont Hospital, Inc Atlanta, GA
- Northside Hospital Cherokee Canton, GA
Medical groups
- Atlanta Diabetes Associates (9 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 850
- Services billed
- 29,165
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 3,480 | 35 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,481 | 602 |
| Hemoglobin a1c level | 1,380 | 575 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 833 | 344 |
| Blood glucose (sugar) measurement using reagent strip | 717 | 357 |
| Blood test, thyroid stimulating hormone (tsh) | 482 | 337 |
| Thyroxine (thyroid chemical), free | 477 | 332 |
| Blood test, comprehensive group of blood chemicals | 449 | 312 |
| Blood test, lipids (cholesterol and triglycerides) | 409 | 294 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 394 | 285 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ozempic (semaglutide) Other prescribers in Atlanta, GA | 313 |
| Levothyroxine Sodium Other prescribers in Atlanta, GA | 186 |
| Atorvastatin Calcium Other prescribers in Atlanta, GA | 159 |
| Rosuvastatin Calcium Other prescribers in Atlanta, GA | 145 |
| Tresiba Flextouch U-100 (insulin degludec) Other prescribers in Atlanta, GA | 132 |
| Metformin Hcl Other prescribers in Atlanta, GA | 121 |
| Losartan Potassium Other prescribers in Atlanta, GA | 102 |
| Nano 2nd Gen Pen Needle (pen needle, diabetic) Other prescribers in Atlanta, GA | 99 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) (insulin pump cart,auto,bt,g6/7) | 91 |
| Humalog (insulin lispro) Other prescribers in Atlanta, GA | 90 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 28 companies reported 129 payments worth $14,398 in total to this clinician.
| Sequel Med Tech, LLC | $6,492 |
|---|---|
| Senseonics, Incorporated | $2,640 |
| Sanofi-aventis U.S. LLC | $1,789 |
| Vertex Pharmaceuticals Incorporated | $1,170 |
| Abbott Laboratories | $447 |
| Novo Nordisk Inc | $300 |
| Beta Bionics, Inc. | $210 |
| Insulet Corporation | $199 |
| Consulting Fee | $4,947 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $4,239 |
| Food and Beverage | $3,047 |
| Travel and Lodging | $2,155 |
| Education | $10.02 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sequel Med Tech, LLC Jun 25, 2025 | Consulting Fee TWIIST · AUTOMATED INSULIN DELIVERY DEVICE | $2,500 |
| Sequel Med Tech, LLC Jun 25, 2025 | Travel and Lodging TWIIST · AUTOMATED INSULIN DELIVERY DEVICE · travel to ATLANTA, GA | $2,155 |
| Sanofi-aventis U.S. LLC Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $1,599 |
| Sequel Med Tech, LLC Jun 25, 2025 | Consulting Fee TWIIST · AUTOMATED INSULIN DELIVERY DEVICE | $1,277 |
| Vertex Pharmaceuticals Incorporated Feb 12, 2025 | Consulting Fee | $1,170 |
| Senseonics, Incorporated Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) Eversense · Endocrinology | $400 |
| Senseonics, Incorporated Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) Eversense · Endocrinology | $400 |
| Senseonics, Incorporated Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) Eversense · Endocrinology | $400 |
| Senseonics, Incorporated Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) Eversense · Endocrinology | $400 |
| Senseonics, Incorporated Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) Eversense · Endocrinology | $400 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Senseonics, Incorporated Jul 28, 2025 | Compensation for services other than consulting (speaking, faculty) Eversense · Endocrinology | $240 |
| Sequel Med Tech, LLC Jun 25, 2025 | Consulting Fee TWIIST · AUTOMATED INSULIN DELIVERY DEVICE | $2,500 |
| Sequel Med Tech, LLC Jun 25, 2025 | Travel and Lodging TWIIST · AUTOMATED INSULIN DELIVERY DEVICE · travel to ATLANTA, GA | $2,155 |
| Sequel Med Tech, LLC Jun 25, 2025 | Consulting Fee TWIIST · AUTOMATED INSULIN DELIVERY DEVICE | $1,277 |
| Amgen Inc. Apr 15, 2025 | Education TEPEZZA · Inflammation/Rare Disease · in-kind | $10.02 |
| Senseonics, Incorporated Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) Eversense · Endocrinology | $400 |
| Senseonics, Incorporated Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) Eversense · Endocrinology | $400 |
| Senseonics, Incorporated Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) Eversense · Endocrinology | $400 |
| Sanofi-aventis U.S. LLC Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $1,599 |
| Senseonics, Incorporated Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) Eversense · Endocrinology | $400 |
| Senseonics, Incorporated Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) Eversense · Endocrinology | $400 |
| Senseonics, Incorporated Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) Eversense · Endocrinology | $400 |
| Vertex Pharmaceuticals Incorporated Feb 12, 2025 | Consulting Fee | $1,170 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 18 industry-funded studies in 2025, from 10 companies. The companies reported $1,102,284 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - Evaluation of the dexcom continuous glucose monitoring (cgm) system survivability and data delivery reliability in adults and pediatrics with type 1 and type 2 diabetes
Dexcom, Inc. - A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and safety of tirzepatide once weekly compared to placebo in adult participants with type 1 diabetes a…
Eli Lilly and Company - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - Twiist Initial Experience Study
Sequel Med Tech, LLC - Multi-session evaluation of the investigational dexcom continuous glucose monitoring (cgm) system in adult participants
Dexcom, Inc. - A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Sanofi US Services Inc. · Recruiting · NCT07088068 - A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433 - Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule
Sanofi US Services Inc. · Active, not recruiting · NCT06812988 - NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Abbott Laboratories
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.